Related Experiment Video
Updated: Jun 28, 2025
07:48
Utilizing Functional Genomics Screening to Identify Potentially Novel Drug Targets in Cancer Cell Spheroid Cultures
Published on: December 26, 2016
11.3K
Targeting Moonlighting Enzymes in Cancer
Chunxu Lin1, Mingyang Yu1, Ximei Wu1
1Center for Drug Research and Development, Guangdong Pharmaceutical University, Guangzhou 510006, China.
Molecules (Basel, Switzerland)
|April 13, 2024
Summary
Moonlighting enzymes, proteins with dual roles, are key drivers in cancer development. Targeting these proteins, like PTP4A3, using protein degradation offers a novel therapeutic strategy for cancer treatment.
Area of Science:
- Biochemistry
- Oncology
- Molecular Biology
Background:
- Moonlighting enzymes perform functions beyond their primary enzymatic activity.
- These proteins play significant roles in cancer development and progression.
- They represent promising targets for novel cancer therapies.
Purpose of the Study:
- To explore the multifaceted roles of moonlighting enzymes in cancer.
- To investigate the mechanisms behind their functional switching.
- To discuss target protein degradation as a therapeutic strategy against these enzymes.
Main Methods:
- Literature review of moonlighting enzymes in cancer.
- Analysis of specific examples: GSK-3, GAPDH, ENO1, and PTP4A3.
- Discussion of the target protein degradation approach.
Main Results:
- Moonlighting enzymes like GSK-3, GAPDH, ENO1, and PTP4A3 are implicated in various cancer hallmarks.
- Understanding their role-switching mechanisms is crucial for therapeutic development.
- PTP4A3, a phosphatase, is highlighted for its enigmatic functions in cancer.
Conclusions:
- Moonlighting enzymes are critical in cancer pathogenesis.
- Targeting these enzymes, particularly PTP4A3, holds therapeutic potential.
- Target protein degradation offers an innovative strategy to combat cancer by eliminating these multifunctional proteins.
Related Concept Videos
02:57Targeted Cancer Therapies
7.6K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.6K
02:50Combination Therapies and Personalized Medicine
4.9K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
4.9K
02:53Adaptive Mechanisms in Cancer Cells
5.7K
Cancer cells accumulate genetic changes at an abnormally rapid rate due to the defects in the DNA repair mechanisms. From an evolutionary perspective, such genetic instability is advantageous for cancer development. Mutant cell lines accumulate a series of beneficial mutations that contribute to their progression into cancer.
Some of the advantages that cancer cells have on normal cells include - enhanced ability to divide without terminally differentiating, induce new blood vessel formation,...
Some of the advantages that cancer cells have on normal cells include - enhanced ability to divide without terminally differentiating, induce new blood vessel formation,...
5.7K
02:40Cancer Stem Cells and Tumor Maintenance
4.9K
Early diagnosis and treatment can often cure cancer. However, even with treatment, residual cells called cancer stem cells (CSC) might remain, often causing tumor recurrence. These cancer stem cells possess the potential for self-renewal and multi-lineage differentiation and are often responsible for the therapeutic resistance displayed in most cancers.
Cancer stem cells are thought to originate from tissue-specific normal stem cells or progenitor cells. The normal stem cells usually reside in...
Cancer stem cells are thought to originate from tissue-specific normal stem cells or progenitor cells. The normal stem cells usually reside in...
4.9K
01:46Electron Transport Chain: Complex I and II
13.1K
The mitochondrial electron transport chain (ETC) is the main energy generation system in the eukaryotic cells. However, mitochondria also produce cytotoxic reactive oxygen species (ROS) due to the large electron flow during oxidative phosphorylation. While Complex I is one of the primary sources of superoxide radicals, ROS production by Complex II is uncommon and may only be observed in cancer cells with mutated complexes.
ROS generation is regulated and maintained at moderate levels necessary...
ROS generation is regulated and maintained at moderate levels necessary...
13.1K
03:03mTOR Signaling and Cancer Progression
3.8K
The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
The mTOR pathway or the...
3.8K